Patient perspectives on de ‐simplifying their single‐tablet co‐formulated antiretroviral therapy for societal cost savings

ConclusionsDe‐simplifying Triumeq® generates large cost savings. Additional savings could be achieved by de‐simplifying other STFs. Both physicians and patients agreed that selective de‐simplification was acceptable; however, it may not be acceptable to every patient. Monitoring the medical and cost impacts of de‐simplification strategies seems warranted.

Source: HIV Medicine - January 25, 2018 Category: Infectious Diseases Authors: HB Krentz, S Campbell, VC Gill, MJ Gill Tags: Original Research Source Type: research